Navigation Links
Mevion Medical Systems Delivers the World's First Superconducting Synchrocyclotron for Proton Therapy to Barnes Jewish Hospital
Date:10/31/2011

LITTLETON, Mass., Oct. 31, 2011 /PRNewswire/ -- Mevion Medical Systems announced today it has delivered the world's first superconducting synchrocyclotron to the S. Lee Kling Center for Proton Therapy at the Siteman Cancer Center at Barnes Jewish Hospital and Washington University School of Medicine in St. Louis MO. This inaugural shipment marks the last phase of the manufacturing of the first MEVION S250 proton accelerator module and the first of many to come deliveries of this revolutionary cancer therapy device.  

The synchrocyclotron was delivered after a 1,200 mile, 4-day trip from Mevion's Headquarters in Littleton MA to St. Louis MO.  "It was a very rewarding day to see our first system leave our factory knowing that what we have achieved may affect and improve the lives of cancer patients," stated Joseph K. Jachinowski, chief executive officer of Mevion Medical Systems. "The innovative design of the MEVION S250 makes adding proton therapy remarkably easier for our hospital partners than what was previously available."

Powered by a TriNiobium Core™, the high-energy proton source of the MEVION S250 will preserve all of the treatment benefits of conventional proton treatment systems while removing the obstacles of size, cost and complexity that have limited the wide adoption of this promising cancer treatment modality. The MEVION S250 Proton Therapy System combines a patented, gantry-mounted proton source with a highly integrated, image-based workflow and robotic patient positioning, making proton therapy a practical clinical reality.

Similar to traditional radiation therapy systems in terms of footprint, workflow, and throughput, the MEVION S250 will easily integrate within existing radiation therapy departments to deliver innovative cancer care in a very conventional way.  "Barnes Jewish Hospital prides itself in providing the most advanced technologies to its patients. We are delighted to add this latest development in radiation therapy to our cancer-fighting arsenal," says Jeff Bradley, MD, director of the S. Lee Kling Center for Proton Therapy at Siteman Cancer Center.

This installation of the MEVION S250 at Barnes Jewish Hospital is to be completed early next year.  Two additional facilities are also in the midst of installation; Robert Wood Johnson University Hospital in New Brunswick, NJ and Oklahoma University in Oklahoma City, OK.  Both of these installations are also to be completed in 2012.

ABOUT MEVION MEDICAL SYSTEMS

Mevion Medical Systems, Inc. (formerly Still River Systems, Inc.) is a radiation therapy company dedicated to advancing the treatment of cancer. As the pioneering developer of modern proton therapy systems, Mevion provides innovative, safe, and effective solutions by transforming advances in medical technology and science into practical clinical reality.

Mevion's flagship product, the MEVION S250 Proton Therapy System, is designed to preserve all of the treatment benefits of traditional proton therapy systems while removing the obstacles of size, cost, and complexity. Realizing this vision, Mevion has forever changed the economics and accessibility of proton therapy worldwide.

Founded in 2004, Mevion is a privately held company headquartered in the Boston metropolitan area with international offices in the United Kingdom and Japan.

The United States Food and Drug Administration has not cleared the MEVION S250 Proton Therapy System for clinical use.

Visit us at: www.mevion.com


'/>"/>
SOURCE Mevion Medical Systems
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
2. You May Have a Thyroid Problem and Not Know It - Particularly If Youre Over 60, Says a New Harvard Medical School Report
3. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
4. Globus Medical Raises $110 Million in Series E Financing Round
5. Quark Pharmaceuticals Appoints New Chief Medical Officer
6. Boston University Biomedical Engineers Find Chink in Bacterias Armor
7. Rochester Medical Anti-Infection Foley Catheter Demonstrates Effectiveness in Randomized Trial
8. Rockwell Medical Technologies, Inc. Begins Patient Enrollment for its SFP Dose-Ranging Study
9. Flexible Medical Systems Raises $1.2M Seed Investment for Initial Human Trials
10. Cleveland Clinic Summits to Focus on Cardiovascular Medical Innovation
11. Rockwell Medical Technologies, Inc. Begins Dosing Patients for SFP Phase IIb Clinical Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... 23, 2016 Any dentist who has made an ... current process. Many of them do not even offer this ... and high laboratory costs involved. And those who ARE able ... such a high cost that the majority of today,s patients ... Parsa Zadeh , founder of Dental Evolutions Inc. and ...
(Date:6/23/2016)... 23, 2016 Capricor Therapeutics, ... a biotechnology company focused on the discovery, development ... patient enrollment in its ongoing randomized HOPE-Duchenne clinical ... 50% of its 24-patient target. Capricor expects the ... quarter of 2016, and to report top line ...
(Date:6/23/2016)... and BOGOTA, Colombia , June 23, 2016  Astellas today announced the establishment of ... Farma Brasil as the company,s second affiliate in Latin America . ... ... Manager of Astellas Farma Colombia ... ...
Breaking Medicine Technology:
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article ... are unfamiliar with. The article goes on to state that individuals are now more ... these less common operations such as calf and cheek reduction. The Los Angeles area ...
(Date:6/24/2016)... ... June 24, 2016 , ... June 19, 2016 is World Sickle ... chronic pain and the benefits of holistic treatments, Serenity Recovery Center of ... Sickle Cell Disease. , Sickle Cell Disease (SCD) is a disorder of the red ...
(Date:6/24/2016)... ... 2016 , ... The Pulmonary Hypertension Association (PHA) learned during ... two significant new grants to support its work to advance research and patient ... recognizing patients, medical professionals and scientists for their work in fighting pulmonary hypertension ...
(Date:6/24/2016)... San Francisco, CA (PRWEB) , ... June 24, ... ... at CitiDent, is now offering micro-osteoperforation for accelerated orthodontic treatment. Dr. Cheng has ... , self-ligating Damon brackets , AcceleDent, and accelerated osteogenic orthodontics. , ...
(Date:6/24/2016)... ... June 24, 2016 , ... Topical BioMedics, Inc, makers of Topricin and MyPainAway Pain Relief Products, ... minimum wage raise to $12 an hour by 2020 and then adjusting it yearly to ... value of the minimum wage, assure the wage floor does not erode again, and make ...
Breaking Medicine News(10 mins):